Screening, library‐assisted identification and validated quantification of fifteen neuroleptics and three of their metabolites in plasma by liquid chromatography/mass spectrometry with atmospheric pressure chemical ionization
- 23 January 2003
- journal article
- research article
- Published by Wiley in Journal of Mass Spectrometry
- Vol. 38 (3) , 283-295
- https://doi.org/10.1002/jms.440
Abstract
A liquid chromatographic/mass spectrometric assay with atmospheric pressure chemical ionization (APCI‐LC/MS) is presented for the fast and reliable screening and identification and for the precise and sensitive quantification of 15 neuroleptic (antipsychotic) drugs and three of their relevant metabolites in plasma. It allows confirmation of the diagnosis of a neuroleptic overdose and monitoring of psychiatric patients' compliance. The neuroleptics amisulpride, bromperidol, clozapine, droperidol, flupenthixol, fluphenazine, haloperidol, melperone, olanzapine, perazine, pimozide, risperidone, sulpiride, zotepine and zuclopenthixol and the pharmacologically active metabolites norclozapine, clozapine N‐oxide and 9‐hydroxyrisperidone were extracted from plasma using solid‐phase extraction and were separated on a Merck LiChroCART column with Superspher 60 RP Select B as the stationary phase. Gradient elution was performed using aqueous ammonium formate and acetonitrile. After screening and identification in the scan mode using the authors' new LC/MS library, the neuroleptics were quantified in the selected‐ion mode. The quantification assay was fully validated. It was found to be selective and proved to be linear from sub‐therapeutic to over therapeutic concentrations for all analytes. The corresponding reference levels are listed. The accuracy and precision data were within the required limits. The analytes were stable in frozen plasma for at least 1 month. The method was successfully applied to several authentic plasma samples from patients treated or intoxicated with various neuroleptics. The validated LC/MS assay has proved to be appropriate for the isolation, separation, screening, identification and quantification of various neuroleptics in plasma for clinical toxicology and therapeutic drug monitoring purposes. Copyright © 2003 John Wiley & Sons, Ltd.Keywords
This publication has 55 references indexed in Scilit:
- Bioanalytical method validation and its implications for forensic and clinical toxicology - A reviewAccreditation and Quality Assurance, 2002
- Validated assay for quantification of oxcarbazepine and its active dihydro metabolite 10‐hydroxycarbazepine in plasma by atmospheric pressure chemical ionization liquid chromatography/mass spectrometryJournal of Mass Spectrometry, 2002
- Tuning compounds for electrospray ionization/in‐source collision‐induced dissociation and mass spectra library searchingJournal of Mass Spectrometry, 2001
- Simultaneous determination of clozapine and its N-desmethyl and N-oxide metabolites in plasma by liquid chromatography/electrospray tandem mass spectrometry and its application to plasma level monitoring in schizophrenic patients.Journal of Pharmaceutical and Biomedical Analysis, 2001
- ‘High throughput’ solid-phase extraction technology and turbo ionspray LC-MS-MS applied to the determination of haloperidol in human plasmaJournal of Pharmaceutical and Biomedical Analysis, 1999
- Plasma Level Monitoring of Olanzapine in Patients With SchizophreniaTherapeutic Drug Monitoring, 1997
- Determination of droperidol in plasma by liquid chromatographyJournal of Pharmaceutical and Biomedical Analysis, 1996
- Monitoring of Plasma Clozapine Levels and Its Metabolites in Refractory Schizophrenic PatientsTherapeutic Drug Monitoring, 1996
- Monitoring plasma levels of fluphenazine during chronic therapy with fluphenazine decanoateJournal of Clinical Pharmacy & Therapeutics, 1995
- Comparative Determination of Flupentixol in Plasma by Gas Chromatography and Radioimmunoassay in Schizophrenic PatientsTherapeutic Drug Monitoring, 1985